Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Merck
Johnson and Johnson
Express Scripts
Mallinckrodt

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR CONCERTA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Concerta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00069927 ↗ Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression Terminated National Cancer Institute (NCI) Phase 2 2003-08-01 RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help.
NCT00069927 ↗ Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression Terminated University of South Florida Phase 2 2003-08-01 RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help.
NCT00151970 ↗ Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD Completed Noven Pharmaceuticals, Inc. Phase 2 2005-06-01 This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.
NCT00151970 ↗ Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD Completed Noven Therapeutics Phase 2 2005-06-01 This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.
NCT00181571 ↗ A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Phase 4 2003-06-01 This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of ADHD symptomatology in adults will be sustained over time.
NCT00181571 ↗ A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder Completed Massachusetts General Hospital Phase 4 2003-06-01 This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of ADHD symptomatology in adults will be sustained over time.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Concerta

Condition Name

Condition Name for Concerta
Intervention Trials
Attention Deficit Hyperactivity Disorder 28
ADHD 12
Attention Deficit Disorder With Hyperactivity 12
Healthy 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Concerta
Intervention Trials
Attention Deficit Disorder with Hyperactivity 61
Hyperkinesis 40
Disease 24
Fatigue 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Concerta

Trials by Country

Trials by Country for Concerta
Location Trials
United States 172
Canada 7
Sweden 3
Switzerland 3
Israel 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Concerta
Location Trials
Massachusetts 18
Ohio 13
Texas 11
California 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Concerta

Clinical Trial Phase

Clinical Trial Phase for Concerta
Clinical Trial Phase Trials
Phase 4 46
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Concerta
Clinical Trial Phase Trials
Completed 63
Unknown status 9
Terminated 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Concerta

Sponsor Name

Sponsor Name for Concerta
Sponsor Trials
Massachusetts General Hospital 14
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. 13
Ortho-McNeil Janssen Scientific Affairs, LLC 10
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Concerta
Sponsor Trials
Other 92
Industry 44
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
McKinsey
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.